What question did this study set out to answer?

Evaluating the efficacy and safety of tixagevimab/cilgavimab in kidney transplant recipients.

Efficacy and Outcome of Tixagevimab-Cilgavimab Prophylaxis Administration in Kidney Transplant Patients

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study found similar incidence of COVID-19 in kidney transplant patients, suggesting tixagevimab-cilgavimab may reduce severity.

Evaluating the efficacy and safety of tixagevimab/cilgavimab in kidney transplant recipients.
Retrospective, single-center study conducted on kidney transplant patients from June 2022 to January 2023.
Patients divided into treatment and control groups based on tixagevimab/cilgavimab therapy status.
Comparison of incidence of COVID-19, acute rejection, hypersensitivity reactions, and cardiac events.
93 patients included in the study, with 38 receiving tixagevimab/cilgavimab.
Prior to administration, 40.9% of participants were infected with COVID-19.
Post-administration, 7.5% developed COVID-19, with no hospitalizations required.

Habibullah et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective study found similar incidence of COVID-19 in kidney transplant patients, suggesting tixagevimab-cilgavimab may reduce severity.